menu search

SUPN / Supernus to Present at the Cowen 43rd Annual Health Care Conference

Supernus to Present at the Cowen 43rd Annual Health Care Conference
ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat, as well as host investor meetings, at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 9:50 a.m. ET. Read More
Posted: Mar 1 2023, 16:55
Author Name: GlobeNewsWire
Views: 103143

SUPN News  

Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics

By Zacks Investment Research
August 8, 2023

Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2023, it could be wort more_horizontal

Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 8, 2023

Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates

Supernus Pharmaceuticals (SUPN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.23. This compares to earni more_horizontal

Supernus: Rebuilding In Progress, But At An Inadequate Pace

By Seeking Alpha
June 12, 2023

Supernus: Rebuilding In Progress, But At An Inadequate Pace

Supernus Pharmaceuticals faces declining revenues from its long-time top seller Trokendi XR due to generic competition. Despite Trokendi's struggles, more_horizontal

Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy

By The Motley Fool
June 10, 2023

Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy

Supernus Pharmaceuticals is facing generic competition for its drug Trokendi. It's also scaling up its revenue for its medicine Qelbree. more_horizontal

Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

By Zacks Investment Research
May 9, 2023

Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to comp more_horizontal

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 9, 2023

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, more_horizontal

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates

By Zacks Investment Research
May 9, 2023

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.12 per share. This com more_horizontal

Supernus to Present at the Cowen 43rd Annual Health Care Conference

By GlobeNewsWire
March 1, 2023

Supernus to Present at the Cowen 43rd Annual Health Care Conference

ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing an more_horizontal


Search within

Pages Search Results: